Emergence of vaccine-related pneumococcal serotypes as a cause of bacteremia

Clinical Infectious Diseases

Volumn 42, Issue 7, 2006, Pages 907-914

  Steenhoff, Andrew P ^a,b   Shah, Samir S ^a   Ratner, Adam J ^a   Patil, Sujata M ^a   McGowan, Karin L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIAL COLONIZATION; CHILD; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; MORAXELLA CATARRHALIS; NEISSERIA MENINGITIDIS; PENICILLIN RESISTANCE; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINE RELATED PNEUMOCOCCAL SEROTYPE;

ADOLESCENT; BACTEREMIA; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; INFANT; MALE; MENINGOCOCCAL VACCINES; PENICILLIN RESISTANCE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE;

EID: 33645085560     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/500941     Document Type: Article

References (33)

1. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000; 19:187-95.
2. Black S, Shinefield H, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002; 21:810-6.
3. Haussdorff WP, Bryant J, Paradiso P, Siber G. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000; 30:100-21.
4. Alpern ER, Alessandrini EA, McGowan KL, Bell LM, Shaw KN. Serotype prevalence of occult pneumococcal bacteremia. Pediatrics 2001; 108:E23.
5. Centers for Disease Control and Prevention Advisory committee on immunization practices. Preventing pneumococcal disease among infants and young children. MMWR Morb Mortal Wkly Rep 2000; 49:1-38.
6. Byington CL, Samore MH, Stoddard GJ, et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin Infect Dis 2005; 41:21-9.
7. Kaplan SL, Mason EO, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 2004; 113:443-9.
8. Black S, Shinefield H, Baxter R, et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J 2004; 23:485-9.
9. Whitney CG, Parley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737-46.
10. Schutze GE, Tucker NC, Mason EO. Impact of the conjugate pneumococcal vaccine in Arkansas. Pediatr Infect Dis J 2004; 23:1125-9.
11. Haddy RI, Perry K, Chacko CE, et al. Comparison of incidence of invasive Streptococcus pneumoniae disease among children before and after introduction of conjugated pneumococcal vaccine. Pediatr Infect Dis J 2005; 24:320-3.
12. Huang SS, Platt R, Rifas-Shiman SL, Pelton SI, Goldman D, Finkelstein JA. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 to 2004. Pediatrics 2005; 116: e408-13.
13. Robbins JB, Lee CJ, Rastogi SC, Schiffman G, Henrichsen J. Comparative immunogenicity of group 6 pneumococcal type 6A (6) and type 6B (26) capsular polysaccharides. Infect Immun 1979; 26:1116-22.
14. Robbins JB, Austrian R, Lee CJ, et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983; 148:1136-59.
15. Talbot TR, Poehling KA, Martert TV, et al. Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2004; 39:641-8.
16. Porat N, Arguedas A, Spratt BG, et al. Emergence of penicillin-non- susceptible Streptococcus pneumoniae clones expressing serotypes not present in the antipneumococcal conjugate vaccine. J Infect Dis 2004; 190:2154-61.
17. Harris AD, Bradham DD, Baumgarten M, Zuckerman IH, Fink JC, Perencevich EN. The use and interpretation of quasi-experimental studies in infectious diseases. Clin Infect Dis 2004; 38:1586-91.
18. Alpern ER, Alessandrini EA, Bell LM, Shaw KN, McGowan KL. Occult bacteremia from a pediatric emergency department: current prevalence, time to detection, and outcome. Pediatrics 2000; 106:505-11.
19. Clinical and Laboratory Standards Institute (formerly NCCLS). Performance standards for antimicrobial susceptibility testing. Fifteenth informational supplement [M100-S15]. Vol. 25. Villanova, PA: Clinical and Laboratory Standards Institute (formerly NCCLS), 2005.
20. Czaja C, Crossette L, Metlay JP. Accuracy of adult reported pneumococcal vaccination status of children. Ann Epidemiol 2005; 15:253-6.
21. Agresti Alan. Categorical data analysis. Hoboken, NJ: John Wiley & Sons, 1990.
22. Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B, Post-vaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. Active Bacterial Core Surveillance Team. J Infect Dis 2005; 192:1988-95.
23. Meats E, Brueggemann AB, Enright MC, et al. Stability of serotypes during nasopharyngeal carriage of Streptococcus pneumoniae. J Clin Microbiol 2003; 41:386-92.
24. Gheradi G, Whitney CG, Facklam RR, Beall B. Major related sets of antibiotic-resistant pneumococci in the United States as determined by pulsed-field gel electrophoresis and pbp1a-pbp2b-pbp2x-dhf restriction profiles. J Infect Dis 2000; 181:216-29.
25. Nesin M, Ramirez M, Tomasz A. Capsular transformation of a multidrug-resistant serotype 23F Streptococcus pneumoniae in vivo. J Infect Dis 1998; 177:707-13.
26. Barnes DM, Whittier S, Gilligan PH, Scares S, Tomasz A, Henderson FW. Transmission of multidrug-resistant serotype 23F Streptococcus pneumoniae in group day care: evidence suggesting capsular transformation of the resistant strain in vivo. J Infect Dis 1995; 171:890-96.
27. Yu X, Gray B, Chang S, Ward JI, Edwards KM, Nahm MH. Immunity to cross reactive serotypes induced by pneumococcal conjugate vaccines in infants. J Infect Dis 1999; 180:1569-76.
28. Väkeväinen M, Eklund C, Eskola J, Käyhty H. Cross-reactivity of antibodies to type 6B and 6A polysaccharides of Streptococcus pneumoniae, evoked by pneumococcal conjugate vaccine in infants. J Infect Dis 2001; 184:789-93.
29. Jakobsen H, Sigurdsson VD, Sigurdardottir S, Schulz D, Jonsdottir I. Pneumococcal serotype 19F conjugate vaccine induces cross-protective immunity to serotype 19A in a murine pneumococcal pneumonia model. Infect Immun 2003; 71:2956-9.
30. Centers for Disease Control and Prevention. Updated recommendations on the use of pneumococcal conjugate vaccine in a setting of vaccine shortage (ACIP). MMWR Morb Mortal Wkly Rep 2001; 50:1140-2.
31. Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. Notice to readers: pneumococcal conjugate vaccine shortage resolved. MMWR Morb Mortal Wkly Rep 2003; 52:446-7.
32. Centers for Disease Control and Prevention. Immunization coverage in the U.S. Available at: http:///www.cdc.gov/nip/coverage/NIS/01/ TAB2-antigen_iap. htm. Accessed 1 August 2005.
33. Hausdorff WP, Siber G, Paradiso PR. Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet 2001; 357:950-2.